Additional file 4 of Development and validation of a psoriasis treatment acceptability measure through group concept mapping

NIAID Data Ecosystem2026-05-01 收录

数据链接：

https://figshare.com/articles/dataset/Additional_file_4_of_Development_and_validation_of_a_psoriasis_treatment_acceptability_measure_through_group_concept_mapping/23908753 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Material 4

创建时间：

2023-08-08

Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

银屑病治疗评估

多准则决策分析

Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight

NIAID Data Ecosystem40

An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis

银屑病治疗评估

药物疗效比较

To undertake a comparison of Cal/BDP cream versus foam for the treatment of plaque psoriasis, with cross-trial population differences accounted for. An anchored matching-adjusted indirect comparison w

Taylor & Francis Group2024-05-16 更新30

Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study

银屑病治疗评估

生物制剂疗效

Objective: This study examined plaque psoriasis (PsO) patient characteristics across injectable biologics. Methods: Data were collected from 400 US dermatologists randomly selecting five charts each f

Figshare2016-01-20 更新00

Additional file 2 of Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting

银屑病治疗评估

生物制剂真实世界研究

Additional File 2: Pairwise difference in Psoriasis Area Severity Index (PASI) from baseline over 12 months receiving Secukinumab among PsO and (PsO-PsA) patients (overall and regarding prior use of b

Figshare2024-08-18 更新40

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

银屑病治疗评估

药物长期安全性

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

NIAID Data Ecosystem10

Additional file 4 of Development and validation of a psoriasis treatment acceptability measure through group concept mapping

资源简介：

相关数据集